Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2013

View Archived Issues

Vectura and UCB collaborate on severe inflammatory diseases

ODM-201 shows efficacy in patients with mCRPC

Discovery and characterization of a novel selective class of anticancer agents

New French biotechnology company formed to develop MAb for ovarian cancer

New FimH inhibitors presented by Vertex Pharmaceuticals

Researchers present promising data for the VEGFR inhibitor cediranib

MEDI-4736 treatment results in significant tumor suppression

FDA clears Beckman Coulter's AccuTnI+3 troponin I assay for UniCel DxI immunoassay systems

VitamFero expands its assets with new vaccine against ocular toxoplasmosis

NICE recommends Genomic Health's Oncotype DX test

MabVax receives SBIR grant for novel pancreatic cancer diagnostic

Moleculin reports encouraging data from phase IIa trial of novel topical psoriasis treatment

Phase II data available for palbociclib in liposarcoma; phase III study planned

Researchers at Boehringer Ingelheim patent novel MCH-R1 antagonists

Karus Therapeutics synthesizes new PI3Kbeta/delta inhibitors

Amgen patents novel tankyrase inhibitors and Wnt activators

Researchers at the University of Maryland divulge new vaccine formulations

GSK to sell thrombosis brands and related manufacturing site to Aspen

Circassia's grass allergy treatment achieves significant symptom reduction in phase II study

FDA grants accelerated approval of new indication for Perjeta

Bone Therapeutics receives clearance to conduct phase I/IIa ALLOB trial

Sun Pharmaceutical and Intrexon to develop new class of drugs for ocular diseases

FDA accepts NDA for tavaborole

Study of LX-4211 in type 2 diabetes patients with renal impairment meets endpoint

Phase I/II trial of Mologen's renal cancer vaccine meets primary endpoints

Antihyperglycemia compound has novel molecular mechanism of action

Novartis initiates pivotal study of HuCAL-derived antibody bimagrumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...